Valneva SE

VALN · NYSE

$5.26−$0.10 (−1.87%)TodayMarket closed · Oct 23, 7:55 PM ET

Prev close $5.36

About VALN

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 694 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Employees: 694
Headquarters: Saint-Herblain, Pays De La Loire
Listed: Jun 28, 2007
Sector: Health Care
Industry: Biotechnology
Website: valneva.com

Leadership

Valneva SE executives
Name	Title	Since	Age
Anne-Marie Graffin	—	—	63
Thomas Lingelbach	—	2012	61
James Sulat	—	2013	74
Peter Buehler	—	—	55
Vincent Dequenne	—	—	57
Petra Pesendorfer	—	—	39
Hanneke Schuitemaker	—	—	61
Kendra Wergin	—	—	39
Franck Grimaud	—	—	58
Juan Jaramillo	—	—	54
Dipal Patel	—	—	51
Mailys Ferrere	—	—	62
Kathrin Jansen	—	—	67
James Connolly	—	—	60
Daniele Guyot-Caparros	—	—	66

Revenue by product and region

Fiscal year ended Dec 31, 2024: $169.58M total revenue

By region

United States$48.59M28.7%
United Kingdom$19.49M11.5%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.